Market Herald logo


Be the first with the news that moves the market

Alexium gained 14.8 per cent today after receiving approval from the US Environmental Protection Agency. Approval was awarded to the company’s Alexiflam product.

Alexiflam is a patent pending flame retardant for cotton and cellulose-based textiles. The approval marks the entrance into the US consumer market for Alexiflam and will boost already present military use.

The product boasts a more environmentally friendly approach to flame retardancy. It also appeals to the market as a stronger and faster solution.

Earlier this month, Alexium also signed a distribution deal with manufacturer Israel Solutions (ICL) for Alexiflam. The deal broke barriers for Alexiflam in the global market.

Alexium CEO Bob Brookings says the ICL deal combined with the US representing the largest global market for flame retardant cotton products is a massive opportunity.

“Having delivered on these milestones, Alexium is well placed to drive the commercialization of [Alexiflam] and deliver on the global opportunities we see for our unique textile technology,” he said.

The US is reported to represent nearly half of the global flame-retardant cotton market.

Please see the announcement attached

AJX by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.